A perspective on LILRBs and LAIR1 as immune checkpoint targets for cancer treatment
- 4 November 2022
- journal article
- research article
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 633, 64-67
Abstract
No abstract availableKeywords
Funding Information
- U.S. Department of War (ME190050)
- National Cancer Institute (1R01CA248736, 1R01CA263079-01A1)
- Cancer Prevention and Research Institute of Texas (RP220032)
- Leukemia and Lymphoma Society (6629–21)
This publication has 14 references indexed in Scilit:
- Leukocyte immunoglobulin-like receptor subfamily B: therapeutic targets in cancerAntibody Therapeutics, 2021
- Dual Targeting to Overcome Current Challenges in Multiple Myeloma CAR T-Cell TreatmentFrontiers in Oncology, 2020
- LILRB4 ITIMs mediate the T cell suppression and infiltration of acute myeloid leukemia cellsCellular & Molecular Immunology, 2019
- LILRB4 signalling in leukaemia cells mediates T cell suppression and tumour infiltrationNature, 2018
- A Novel Anti-LILRB4 CAR-T Cell for the Treatment of Monocytic AMLMolecular Therapy, 2018
- Fundamental Mechanisms of Immune Checkpoint Blockade TherapyCancer Discovery, 2018
- Interleukin 6 Is Not Made By Chimeric Antigen Receptor T Cells and Does Not Impact Their FunctionBlood, 2016
- Inhibitory leukocyte immunoglobulin-like receptors: Immune checkpoint proteins and tumor sustaining factorsCell Cycle, 2016
- Inhibitory receptors bind ANGPTLs and support blood stem cells and leukaemia developmentNature, 2012
- HLA-G homodimer-induced cytokine secretion through HLA-G receptors on human decidual macrophages and natural killer cellsProceedings of the National Academy of Sciences, 2009